Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Palmetto Park Place PONTE VEDRA FL 32081 |
Tel: | N/A |
Website: | https://www.treace.com |
IR: | See website |
Key People | ||
James T. Treace Chairman of the Board | John T. Treace Chief Executive Officer, Founder, Director | Mark L. Hair Chief Financial Officer |
Aaron J. Berutti Senior Vice President - Sales | Nathan Minnich Senior Vice President - Marketing | Scot Michael Elder Chief Legal Officer, Chief Compliance Officer, Corporate Secretary |
Julie D. Dewey Chief Communications, Investor Relations Officer | Sean F. Scanlan Chief Innovation Officer |
Business Overview |
Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States. |
Financial Overview |
For the fiscal year ended 31 December 2023, Treace Medical Concepts Inc revenues increased 32% to $187.1M. Net loss increased 16% to $49.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 39% to $120.2M (expense), General and administrative - Balancing increase of 28% to $36.5M (expense). |
Employees: | 516 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $567.75M as of Dec 31, 2023 |
Annual revenue (TTM): | $187.12M as of Dec 31, 2023 |
EBITDA (TTM): | -$46.00M as of Dec 31, 2023 |
Net annual income (TTM): | -$49.53M as of Dec 31, 2023 |
Free cash flow (TTM): | -$46.03M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 61,936,000 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |